<DOC>
	<DOCNO>NCT02792491</DOCNO>
	<brief_summary>This Phase II prospective trial addition rituximab reduce dose CHOP chemotherapy DLBC L patient age 65 year .</brief_summary>
	<brief_title>Phase II Prospective Trial Addition Rituximab Reduced Dose CHOP Chemotherapy DLBC L Patients Aged 65 Years Over</brief_title>
	<detailed_description>The body surface area ( BSA ) date every treatment cycle may use value baseline BSA , change body weight within 10 % baseline body weight . But , change body weight 10 % baseline , BSA recalculate . It repeat every 21 day . But change start date subsequent cycle laboratory radiologic test may allow within 4 day schedule date delay due toxicity . The RD-RCHOP treatment continue 6-8 cycle ( 3 cycle case stable disease ( SD ) progressive disease ( PD ) first 3cycles ) duration 21 day . Visit windows ± 4days Treatment period .</detailed_description>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Histologically confirm CD20 positive DLBCL 2 . Age ≥ 65 year 3 . Ann Arbor stage II , III IV 4 . No prior chemotherapy radiotherapy DLBCL 5 . Performance status ( ECOG ) ≤ 2 6 . At least one bidimensionally measurable lesion ( ) 2 cm conventional CT 1 cm spiral CT skin lesion ( photograph take ) ≥ 2 cm measurable lesion physical examination ≥ 2 cm 7 . Cardiac ejection fraction ≥ 50 % measure MUGA 2DECHO without clinically significant abnormality 8 . Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) 9 . Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) Bilirubin &lt; 2 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) 10 . Adequate BM function : hemoglobin ≥ 9 g/dL absolute neutrophil count ( ANC ) ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma 11 . Life expectancy 6 month 12 . A negative serum urine pregnancy test prior treatment must available premenopausal woman woman &lt; 1years onset menopause . 13 . Informed consent 1 . Other subtypes NHL DLCBL 2 . Patients transform follicular lymphoma indolent lymphoma 3 . Primary Central Nervous System ( CNS ) DLBCL 4 . CNS involvement lymphoma evidence spinal cord compression . Brain CT/MRI mandatory ( within 4 week ) case clinical suspicion CNS involvement lymphoma . Patients prophylactic intrathecal chemotherapy CNS disease eligible . 5 . Patients known history HIV seropositivity HCV ( + ) . Patients HBV ( + ) eligible . However , primary prophylaxis use antiviral agent ( i.e . lamivudine ) recommend HBV carrier prevent HBV reactivation whole treatment period . 6 . Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 7 . Pregnant lactate woman , woman childbearing potential employ adequate contraception 8 . Other serious illness medical condition i. Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry ii . History significant neurologic psychiatric disorder include dementia seizure iii . Active uncontrolled infection ( viral , bacterial fungal infection ) iv . Other serious medical illness 9 . Known hypersensitivity study drug ingredient ( i.e. , hypersensitivity Polysorbate 20 , CHO cell product , recombinant human antibody ) 10 . Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>